Bisantrene
- Generic Name
- Bisantrene
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22N8
- CAS Number
- 78186-34-2
- Unique Ingredient Identifier
- 39C34M111K
Race Oncology's RC220 Phase 1 Trial Advances for Solid Tumors
• Race Oncology has submitted ethics and regulatory documents for a Phase 1 trial of RC220 with doxorubicin, targeting advanced solid tumors.
• The trial, expected to begin in Q1 2025, will assess the safety and tolerability of RC220 in combination with doxorubicin across multiple sites.
• The study includes two stages focusing on dose optimization, cardioprotective benefits, and anticancer efficacy of RC220.
• Race Oncology also reported $18.78 million in cash reserves, with significant investment in R&D and drug manufacturing.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath